Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled with 68Ga and 177Lu as Potential Theranostic Agents

Salvanou, Evangelia-Alexandra; Kolokithas-Ntoukas, Αrgiris; Liolios, Christos; Xanthopoulos, Stavros; Paravatou-Petsotas, Maria; Tsoukalas, Charalambos; Avgoustakis, Konstantinos; Bouziotis, Penelope

doi:10.3390/nano12142490

Cited by 9 publications

(12 citation statements)

References 68 publications

(103 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Salvanou et al ( 2022 ) constructed calcium alginate and PEGylated magnetic iron oxide NPs (MIONPs; ~ 120 nm) and labeled these to high efficiency (90–95%) by direct binding of 177 Lu or 68 Ga in Na acetate buffer, pH 5.5 or 4.0, respectively, heated at 75 °C for 30 min. 177 Lu or 68 Ga-labeled MIONPs were relatively stable in serum (> 70% up 7 d at 37 °C).…”

Section: Main Textmentioning

confidence: 99%

Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape

Reilly,

Georgiou,

Brown

et al. 2024

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Background Radiation nanomedicines are nanoparticles labeled with radionuclides that emit α- or β-particles or Auger electrons for cancer treatment. We describe here our 15 years scientific journey studying locally-administered radiation nanomedicines for cancer treatment. We further present a view of the radiation nanomedicine landscape by reviewing research reported by other groups. Main body Gold nanoparticles were studied initially for radiosensitization of breast cancer to X-radiation therapy. These nanoparticles were labeled with 111In to assess their biodistribution after intratumoural vs. intravenous injection. Intravenous injection was limited by high liver and spleen uptake and low tumour uptake, while intratumoural injection provided high tumour uptake but low normal tissue uptake. Further, [111In]In-labeled gold nanoparticles modified with trastuzumab and injected iintratumourally exhibited strong tumour growth inhibition in mice with subcutaneous HER2-positive human breast cancer xenografts. In subsequent studies, strong tumour growth inhibition in mice was achieved without normal tissue toxicity in mice with human breast cancer xenografts injected intratumourally with gold nanoparticles labeled with β-particle emitting 177Lu and modified with panitumumab or trastuzumab to specifically bind EGFR or HER2, respectively. A nanoparticle depot (nanodepot) was designed to incorporate and deliver radiolabeled gold nanoparticles to tumours using brachytherapy needle insertion techniques. Treatment of mice with s.c. 4T1 murine mammary carcinoma tumours with a nanodepot incorporating [90Y]Y-labeled gold nanoparticles inserted into one tumour arrested tumour growth and caused an abscopal growth-inhibitory effect on a distant second tumour. Convection-enhanced delivery of [177Lu]Lu-AuNPs to orthotopic human glioblastoma multiforme (GBM) tumours in mice arrested tumour growth without normal tissue toxicity. Other groups have explored radiation nanomedicines for cancer treatment in preclinical animal tumour xenograft models using gold nanoparticles, liposomes, block copolymer micelles, dendrimers, carbon nanotubes, cellulose nanocrystals or iron oxide nanoparticles. These nanoparticles were labeled with radionuclides emitting Auger electrons (111In, 99mTc, 125I, 103Pd, 193mPt, 195mPt), β-particles (177Lu, 186Re, 188Re, 90Y, 198Au, 131I) or α-particles (225Ac, 213Bi, 212Pb, 211At, 223Ra). These studies employed intravenous or intratumoural injection or convection enhanced delivery. Local administration of these radiation nanomedicines was most effective and minimized normal tissue toxicity. Conclusions Radiation nanomedicines have shown great promise for treating cancer in preclinical studies. Local intratumoural administration avoids sequestration by the liver and spleen and is most effective for treating tumours, while minimizing normal tissue toxicity.

show abstract

Section: Main Textmentioning

confidence: 99%

Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape

Reilly,

Georgiou,

Brown

et al. 2024

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

show abstract

“…[22] Moreover, other substances, such as dendrimers and alginate could also be used to coat SPIO nanoparticles for radiolabeling with 68 Ga and in this way acquiring PET/MRI images. [19,23] Rather than only being applied as PET/MR imaging probes, the FeO x nanoparticles with versatile properties have shown the potential for other clinical applications. A typical example is to use the FeO x -based nanoplatform as theragnostic agents.…”

Section: Iron-based Nanoparticles For Pet/mr Imagingmentioning

confidence: 99%

Section: Nano‐sized Pet/mr Bifunctional Probesmentioning

confidence: 99%

Nanoprobes for PET/MR Imaging

Liu,

Wang,

Gao

et al. 2023

Advanced Therapeutics

View full text Add to dashboard Cite

The development of clinical imaging techniques significantly improves diagnostic accuracy and provides guidance for personalized treatment of individuals. However, every single imaging modality has its distinct drawbacks that cannot fully fulfil the diagnosis requirement. Thus, rational combination of different imaging modalities can achieve more comprehensive information of disease and in this way provide better personalized treatment strategy. The hybrid PET/MRI has drawn increasing attention since its first clinical application. Imaging probes play an essential role in achieving qualified figures with accurate information of diseases. The application of nanotechnology promotes the development of versatile molecular probes for PET/MRI technique. Though there is an emerging clinical requirement, only a small number of multimodal PET/MRI probes have been investigated in preclinical research. Thus, in this review, we try to thoroughly summarize the nano‐sized PET/MRI probes on their design, preparation and biological application. By discussing the strength and limitations of these current available PET/MRI multimodal probes, we aimed to figure out the further research direction and promote the possible clinic translation of the novel PET/MRI probes.This article is protected by copyright. All rights reserved

show abstract

“…The nanoparticles IONs, IONs-SH, IONs-PSMA, IONs-BN and IONs-PSMA/BN were characterized for their size and zeta potential (ζp), using DLS, and FT-IR according to standard procedures (32,39,40). Briefly, the DLS experiments (Figure 1) showed that their size of ranged between 25.5 and 121.3 nm, and it remained small even after their functionalization (e.g., IONs-SH: 54.5 nm, IONs-PSMA: 64.8 nm), possibly due to the small size of the bound peptides.…”

Section: Characterization Of the Ionsmentioning

confidence: 99%

Radiolabeled iron oxide nanoparticles functionalized with PSMA/BN ligands for dual-targeting of prostate cancer

Bajwa,

Salvanou,

Theodosiou

et al. 2023

Front. Nucl. Med.

Self Cite

View full text Add to dashboard Cite

IntroductionProstate cancer (PCa) is the second most frequent cancer diagnosis in men and the fifth leading cause of death worldwide. Prostate Specific Membrane Antigen (PSMA) and Gastrin Releasing Peptide (GRP) receptors are overexpressed in PCa. In this study, we have developed iron oxide nanoparticles (IONs) functionalized with the Prostate Specific Membrane Antigen (PSMA) and Gastrin Releasing Peptide (GRP) ligands for dual targeting of Prostate cancer.MethodsIONs were developed with a thin silica layer on their surface with MPTES (carrying -SH groups, IONs-SH), and they were coupled either with a pharmacophore targeting PSMA (IONs-PSMA) or with bombesin peptide (IONs-BN), targeting GRP receptors, or with both (IONs-PSMA/BN). The functionalized IONs were characterized for their size, zeta potential, and efficiency of functionalization using dynamic light scattering (DLS) and Fourier-Transform Infrared Spectroscopy (FT-IR). All the aforementioned types of IONs were radiolabeled directly with Technetium-99m (99mTc) and evaluated for their radiolabeling efficiency, stability, and binding ability on two different PCa cell lines (PC3 and LNCaP).Results and DiscussionThe MTT assay demonstrated low toxicity of the IONs against PC3 and LNCaP cells, while the performed wound-healing assay further proved that these nanostructures did not affect cellular growth mechanisms. The observed hemolysis ratio after co-incubation with red blood cells was extremely low. Furthermore, the 99mTc-radiolabeled IONs showed good stability in human serum, DTPA, and histidine, and high specific binding rates in cancer cells, supporting their future utilization as potential diagnostic tools for PCa with Single Photon Emission Computed Tomography (SPECT) imaging.

show abstract

Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled with 68Ga and 177Lu as Potential Theranostic Agents

Cited by 9 publications

References 68 publications

Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape

Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape

Nanoprobes for PET/MR Imaging

Radiolabeled iron oxide nanoparticles functionalized with PSMA/BN ligands for dual-targeting of prostate cancer

Contact Info

Product

Resources

About